سعر ارجوكونازول 200مجم 10 اقراص 2022

Ergoconazol 200 mg (voriconazole) film-coated tablets, pack of 10 (Egypt).

• Invasive aspergillosis (adults and children ≥ 2 years).Population: Adults and pediatric patients ≥ 2 yearsDailyMed (U.S. National Library of Medicine)
• Candidemia in non-neutropenic patients and deep-tissue Candida infections (disseminated skin infections and infections of abdomen, kidney, bladder wall and wounds).Population: Adults and pediatric patients ≥ 2 yearsDailyMed (U.S. National Library of Medicine)
• Esophageal candidiasis.Population: Adults and pediatric patients ≥ 2 yearsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (incidence ≥ 2%): visual disturbances (18.7%), fever, nausea, rash, vomiting, chills, headache, liver function test abnormal, tachycardia and hallucinations.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to voriconazole or its excipients (caution with cross-sensitivity to other azoles).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Co-administration with CYP3A4 substrates whose raised levels can cause QT prolongation/torsade de pointes or other serious toxicity, e.g. pimozide, quinidine, ivabradine, sirolimus, ergot alkaloids (ergotamine, dihydroergotamine), naloxegol, tolvaptan, lurasidone, eplerenone, finerenone, voclosporin, venetoclax (ramp-up phase in CLL).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Co-administration with strong inducers that markedly lower voriconazole levels: rifampin, rifabutin, carbamazepine, long-acting barbiturates, St John's wort, efavirenz ≥ 400 mg/day and high-dose ritonavir (400 mg every 12 h).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hepatic toxicity (including fulminant hepatic failure): measure transaminases and bilirubin at initiation and at least weekly for the first month, then monitor regularly.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• QT prolongation and arrhythmias (including torsade de pointes): use with caution in proarrhythmic conditions; correct hypokalaemia, hypomagnesaemia and hypocalcaemia before starting.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Visual disturbances: monitor visual acuity, visual field and colour perception if treatment continues beyond 28 days.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• CYP3A4 substrates with narrow therapeutic index (pimozide, quinidine, ivabradine, sirolimus, ergot alkaloids, etc.)Voriconazole increases their concentrations (QT prolongation, ergotism and other toxicity); contraindicated.DailyMed (U.S. National Library of Medicine)
• Rifampin, rifabutin, carbamazepine, long-acting barbiturates, St John's wortMarkedly decrease voriconazole exposure (rifabutin levels also rise); contraindicated.DailyMed (U.S. National Library of Medicine)
• Phenytoin; efavirenz (standard dose)Lower voriconazole exposure; the voriconazole maintenance dose must be increased (and efavirenz dose reduced) when co-administered.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm when administered to a pregnant woman (teratogenic in rats – cleft palates, hydronephrosis/hydroureter; embryotoxic in rabbits). Advise females of reproductive potential to use effective contraception during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk or effects on the breastfed infant; weigh benefits of breastfeeding against the mother's need for therapy.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Voriconazole: Inhibits fungal cytochrome P450-dependent 14-alpha-lanosterol demethylation, blocking ergosterol synthesis.